Optellum
Optellum develops FDA-cleared AI software for early lung cancer detection and lung nodule risk stratification, serving hospitals, health systems, and life sciences companies across the US, UK, and Australia with a Medicare-reimbursable platform.
- Company typePrivate
- Founded2016
- HeadquartersOxford, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What Optellum does
Optellum is an Oxford-headquartered medtech company, founded in 2016 as a spinout from the University of Oxford, that develops AI-powered software for early lung cancer detection and lung nodule management. Its core platform, the Virtual Nodule Clinic (VNC), combines three proprietary technologies: Lung Cancer Prediction (LCP) AI, a deep learning and radiomics model that analyzes chest CT images to produce a malignancy risk score and is described as the world's only FDA-cleared and UKCA/CE-marked reimbursable radiomics AI for lung cancer diagnosis; Patient Discovery AI, which uses NLP to run overnight searches across radiology reports (reported at 100% sensitivity and 98% specificity); and workflow management tools for triage, tracking, and care coordination. The company has developed what it calls the world's first thorax CT foundation model and offers adjacent modules including LCP Maxscreen (5-year population risk), LungRecur (post-surgical recurrence prediction), and Virtual Nodule Clinic Pro (end-to-end automation).
The company's revenue model rests on three streams: enterprise SaaS subscriptions to hospitals, health systems, and imaging centers; per-use Medicare reimbursement at $650 per LCP analysis; and partnerships with life sciences companies (Bristol Myers Squibb, GE Healthcare, Johnson & Johnson, Concert AI) for clinical development, patient enrollment, and commercial applications. As of mid-2026, Optellum reported deployments at 250+ clinical sites spanning the US, UK, and Australia, with over 3 million cases analyzed. Named enterprise customers include University of Pennsylvania Health System, Vanderbilt University Medical Center, Atrium Health, Penn Medicine, UConn Health, Jupiter Medical Center, Georgia Cancer Center, and NHS trusts in London. The go-to-market combines direct enterprise sales with embedded distribution through partnerships with Intuitive Surgical (robotic bronchoscopy), GE Healthcare (imaging), and life sciences co-development deals.
Optellum firmographics
Firmographics- Name
- Optellum
- Legal name
- Optellum Ltd.
- Website
- https://optellum.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Optellum develops FDA-cleared AI software for early lung cancer detection and lung nodule risk stratification, serving hospitals, health systems, and life sciences companies across the US, UK, and Australia with a Medicare-reimbursable platform.
- Ownership category
- akta.pro rank
Optellum industry classification
Industry- Product category
- Clinical Decision Support / Medical Imaging AI for Lung Cancer Diagnosis
- NAICS
- Computer Systems Design and Related Services (54151)
- SIC
- Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
- akta.pro secondary industries
- Lung Cancer Screening & Pulmonary Nodule Clinic (HLAKANAI), Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM), Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic) (HLACALAD)
Keywords
Where Optellum is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Optellum business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations
Revenue model
- Virtual Nodule Clinic Licensing: SaaS-based licensing model for the Virtual Nodule Clinic platform, providing AI-powered lung nodule risk stratification and care coordination tools to healthcare providers. Revenue generated through subscription licensing with healthcare systems and hospitals.
- Medicare Reimbursement (Per Use): Optellum's LCP AI is reimbursable under Medicare at $650 per use. This creates a per-procedure revenue stream that supplements subscription licensing.
- Life Sciences Partnerships: Partnerships with biopharma companies (Bristol Myers Squibb) and MedTech companies (GE Healthcare, Johnson & Johnson) for clinical development, patient enrollment acceleration, and commercial applications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise hospital/health system licensing |
| Usage-based | Pay-as-you-go | Medicare per-use reimbursement |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Optellum product offering
Product offeringCore offering
Optellum provides an AI-powered lung precision care platform built around its FDA-cleared Virtual Nodule Clinic (VNC), combining radiomics, deep learning, and NLP to discover lung nodules in radiology reports, predict malignancy risk from chest CT images, and coordinate triage and follow-up workflows. The platform integrates with hospital EHR (Epic, Oracle Cerner) and PACS systems via HL7 and DICOM, and is sold primarily as enterprise SaaS to hospitals, health systems, and imaging centers. A secondary set of offerings targets biopharma and MedTech partners through co-development, patient enrollment, and real-world evidence collaborations.
Product overview
Optellum offers a unified lung precision care platform centered on its Virtual Nodule Clinic (VNC), which serves as the core product for early lung cancer diagnosis. The platform is powered by three interconnected AI technologies: Lung Cancer Prediction (LCP) AI (FDA-cleared, reimbursable radiomics solution for malignancy risk scoring), Patient Discovery AI (automated NLP-based nodule finding from radiology reports), and workflow management tools (triage, tracking, and patient dashboards). Additional products include LCP Maxscreen (population health screening), Zero-click LCP (automated radiology workflow augmentation), and Virtual Nodule Clinic Pro (combining core technologies). The company is expanding into a broader LungOS platform with products like LungDetect (European launch) and LungRecur (recurrence prediction). The architecture follows a platform-plus-modules approach where VNC serves as the foundation, with specialized add-on modules targeting specific use cases in screening, population health, and treatment optimization.
Differentiator
Problem solved
Functional benefit
Brands
- Virtual Nodule Clinic (VNC): AI-powered early lung cancer diagnosis solution for discovering, tracking, and assessing risk of malignancy in lung nodule patients. The world's only FDA-cleared and UKCA/CE-marked reimbursable radiomics AI solution for lung cancer diagnosis.
- Lung Cancer Prediction (LCP) AI
- Patient Discovery AI
- LungOS
- Lung Cancer Screening (LCS)
Products and services
- Virtual Nodule Clinic (VNC) AI-powered early lung cancer diagnosis solution for discovering, tracking, and assessing malignancy risk in lung nodule patients, integrating with EHR and PACS systems and combining Optellum's LCP AI, Patient Discovery AI, and triage/management workflows. Sold to hospitals, health systems, and imaging centers as enterprise software.
- Lung Cancer Prediction (LCP) AI The world's only FDA-cleared, UKCA/CE-marked, and reimbursable radiomics AI solution for lung cancer diagnosis, using deep learning and radiomics on chest CT images to produce a malignancy risk score that outperforms standard-of-care models such as Brock and Mayo. Sold to healthcare providers and reimbursable under Medicare at approximately $650 per use.
- Lung Cancer Screening (LCS) Solution Complete solution for lung cancer screening programs that helps health systems, hospitals, and imaging centers manage screening efficiently and precisely through centralized patient tracking, automated follow-up alerts, and EHR/PACS integration.
- LungOS AI-powered lung health platform positioned as the operating system for thoracic care, expanding Optellum's offering beyond lung cancer diagnosis into a broader lung health platform.
Quantifiable outcome
- 71% more interventional procedures at hospitals using Virtual Nodule Clinic
- +6 more outcomes
Companies that use Optellum
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles3 records
Optellum technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability8 records
Feature7 records
Optellum partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- Tanner HealthcoreRegional health system partnership to launch Optellum's Virtual Nodule Clinic AI platform, serving patients across west Georgia and east Alabama. One of the first regional health systems in Georgia to implement FDA-cleared AI technology system-wide.
- Healthliant VenturesminorPartner with Tanner Health and Optellum to bring AI lung health solutions to the region.
- Massive BiocoreCollaboration to connect AI-powered lung cancer detection with clinical trial matching for early-stage NSCLC patients. Optellum's FDA-cleared LCP AI identifies high-risk patients, whose data is processed by Massive Bio's platform to match with geographically accessible clinical trials.
- Guy's and St Thomas' NHS Foundation TrustcorePilot program location for NHS integration of Optellum's FDA-cleared AI-powered Virtual Nodule Clinic with robotic-assisted bronchoscopy. This is the first NHS integration of AI diagnostic software with robotic-assisted bronchoscopy.
- King's College Hospital NHS Foundation TrustcorePlanned expansion site for NHS pilot program integrating Optellum's AI platform with robotic-assisted bronchoscopy for lung cancer diagnostics.
- Lewisham and Greenwich NHS TrustcorePlanned expansion site for NHS pilot program integrating Optellum's AI platform with robotic-assisted bronchoscopy for lung cancer diagnostics.
- Bristol Myers SquibbcoreFirst-of-its-kind partnership to evaluate real-world impact of AI on patient outcomes. Bristol Myers Squibb is evaluating Optellum's AI platform for lung cancer care optimization.
- Intuitive SurgicalcorePartnership with NHS in the UK to integrate Optellum's AI diagnostic software with robotic-assisted bronchoscopy. Intuitive Surgical provides robotic surgical systems.
- GE HealthcarecoreCollaboration with GE Healthcare for lung cancer diagnosis and treatment. GE Healthcare is a major medical imaging and digital solutions provider.
- Johnson & JohnsoncoreCollaboration for lung cancer diagnosis and treatment expansion. Johnson & Johnson is a major healthcare conglomerate with pharmaceutical and medical device businesses.
- University of OxfordcoreOptellum is a 2016 spinout from the University of Oxford. Ongoing academic partnership for research collaboration, biomarker development, and clinical validation.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Optellum competitors and assessment
Company assessmentDirect peers
- Lunit: South Korea-based AI company developing deep-learning solutions for cancer detection, including lung nodule and chest X-ray AI (Lunit INSIGHT CXR/Nodule). Directly competes with Optellum in lung cancer imaging AI and is more broadly scaled with public-market access.
- Qure.ai: AI radiology company offering FDA-cleared solutions for chest CT and X-ray interpretation, including lung nodule detection and TB screening. Direct competitor to Optellum in AI lung nodule detection with overlapping hospital customer base.
- Riverain Technologies: Provides ClearRead CT and ClearRead XR AI tools for lung nodule detection and chest X-ray interpretation, with established US hospital deployments. Directly competes with Optellum's lung nodule AI offering.
- Aidoc: Broad radiology AI platform offering FDA-cleared algorithms across multiple anatomies including chest CT, with similar enterprise health-system GTM. While not lung-nodule-only, it directly overlaps Optellum's provider customer base and product category.
- Annalise.ai: Comprehensive radiology AI platform covering chest X-ray and CT findings including lung nodules. Direct competitor to Optellum in AI lung imaging with similar regulatory and enterprise GTM approach.
- DeepHealth (RadNet subsidiary): AI-powered imaging subsidiary of RadNet offering lung and broader radiology AI. Competitor in lung nodule and screening workflows with the backing of one of the largest US imaging network operators.
Emerging players
- Behold.ai: UK-based radiology AI company with FDA-cleared chest X-ray and CT triage algorithms. Emerging peer with overlapping lung imaging focus and similar UK heritage to Optellum.
- icometrix: AI imaging company focused on brain MRI (icobrain) with FDA clearance and similar enterprise hospital GTM. Adjacent peer with comparable regulatory and reimbursement model applicable to Optellum's lung platform strategy.
Broad incumbents
- Siemens Healthineers (AI-Rad Companion): Major medical imaging OEM offering AI-Rad Companion platform with lung CT analysis capabilities. Broad incumbent that bundles AI features into enterprise imaging equipment contracts, competing with Optellum at the procurement level.
- GE Healthcare (Edison Platform): Global imaging OEM and partner of Optellum with its own Edison AI platform and lung CT analytics. Serves as both a channel partner and a potential competitive threat as it expands native AI offerings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Optellum social profiles
Digital presenceOptellum compliance and trust
Trust signalCompliance7 records
Optellum financial estimates
Financial estimateRevenue estimate
Valuation estimate
Optellum leadership team
Management profileNumber of profiles
Profiles1 record
Optellum subsidiaries and ownership
Company hierarchySubsidiaries1 record
Optellum funding detail
Funding detailFunding overview
Funding rounds3 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Optellum M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Optellum
What does Optellum do?
Optellum provides an AI-powered lung precision care platform built around its FDA-cleared Virtual Nodule Clinic (VNC), combining radiomics, deep learning, and NLP to discover lung nodules in radiology reports, predict malignancy risk from chest CT images, and coordinate triage and follow-up workflows. The platform integrates with hospital EHR (Epic, Oracle Cerner) and PACS systems via HL7 and DICOM, and is sold primarily as enterprise SaaS to hospitals, health systems, and imaging centers. A secondary set of offerings targets biopharma and MedTech partners through co-development, patient enrollment, and real-world evidence collaborations.
Is Optellum a public or private company?
Optellum is a private company. It is classified as venture growth investor backed and is currently operating.
When was Optellum founded?
Optellum was founded in 2016. It employs 51 to 100 people.
Where is Optellum based?
Optellum is headquartered in Oxford, United Kingdom, in the Europe region.
How does Optellum make money?
Three revenue lines are on record. Virtual Nodule Clinic Licensing is the primary driver. The others are medicare Reimbursement (Per Use) and life Sciences Partnerships.
Who are Optellum's main competitors?
Direct peers on record are Lunit, Qure.ai, Riverain Technologies, Aidoc, Annalise.ai and DeepHealth (RadNet subsidiary). Emerging players are Behold.ai and icometrix. Broad incumbents are Siemens Healthineers (AI-Rad Companion) and GE Healthcare (Edison Platform).
Does Optellum have an API?
No public API is recorded for Optellum.
What industry is Optellum in?
Optellum's product category is Clinical Decision Support / Medical Imaging AI for Lung Cancer Diagnosis. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLAKANAI, Lung Cancer Screening & Pulmonary Nodule Clinic. Its NAICS code is 54151 and its SIC code is 8090.